Tresiba

Chemical Nameinsulin degludec
Dosage FormInjection (subcutaneous; 300 units/3 mL, 600 units/3 mL, 1000 units/10 mL)
Drug ClassHormones
SystemEndocrine
CompanyNovo
Approval Year2015

Indication

  • To improve blood sugar (glucose) control in adults with diabetes mellitus.
Last updated on 10/19/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Tresiba (insulin degludec) Prescribing Information2019Novo Nordisk Inc., Plainsboro, NJ